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Abstract
Background: There is evidence of an association between mediators of inflammation, particularly C-reactive protein 
(CRP), and outcome of acute ischaemic stroke. This provides a potential opportunity for interventions aimed at improving 
outcome. There is sparse data exploring the role of inflammatory markers such as CRP and stroke outcome in Africans. 
The study objective was to determine the association between admission serum CRP levels and short-term outcome 
in the Nigerian patient presenting with acute ischaemic stroke.
Materials and Methods: Consecutive patients hospitalized for first-ever acute ischaemic stroke at the Lagos University 
Teaching Hospital, Lagos, Nigeria, were prospectively enrolled between October 2007 and June 2008. Stroke severity 
was assessed using the National Institutes of Health Stroke Scale (NIHSS). Serum CRP was determined on samples 
obtained within 7 days of stroke onset. All stroke patients were followed up till day 30 post-stroke. Outcome measures 
were 30 day Glasgow outcome scale score and functional impairment on the modified Rankin Scale (mRS). An age- and 
gender-matched healthy control group had serum CRP determined at inclusion. Elevated CRP was defined as any 
level above the cutoff (mean  +2 x standard deviation of CRP level of controls).
Results: Eighty patients with acute ischaemic stroke (47 men and 33 women) and 40 controls (27 male and 13 female) 
(P = 0.47) were studied. Mean age in cases was 59.1 ± 15.0 years. Mean CRP was significantly higher in stroke cases than 
controls (17.7 ± 14.4 mg/L versus 1.1 ± 1.7 mg/L respectively) (P < 0.00001). The frequency of elevated CRP (>4.5 mg/L) 
was 76.3% in stroke (N = 61) and 5% (N = 2) in controls (P < 0.0001). The case fatality rate in stroke with elevated CRP 
(32.8%) was significantly higher than stroke with normal admission CRP (0%; P = 0.015). The association of higher admission 
CRP with fatality () was statistically significant (P < 0.0001). Amongst survivors, mean CRP levels were markedly higher 
in the patients with unfavorable motor outcome (moderate/severe disability; n = 22; 21.5 ± 11.1) compared to those with 
favorable outcome (mild disability; n = 38; 6.5 ± 6.2) (P < 0.00001). In multivariate regression analysis, only high NIHSS 
score (P = 0.004) and admission CRP (P = 0.008) were independently associated with case fatality.
Conclusions: Elevated admission CRP and high NIHSS score are independent predictors of short-term case fatality 
and adverse functional outcome following acute ischaemic stroke in Nigerians.
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Introduction
The burden of stroke in low and middle income countries 
is likely to rise substantially over the next few decades as 
a result of an increase in the prevalence of cardiovascular 
risk factors and a contemporaneous demographic transition. 
Stroke has been highlighted as a leading indication for 
medical emergency room admissions in sub Saharan 
Africa.[1,2] At present, stroke mortality in sub Saharan Africa 
is high, with most hospital series reporting case fatality 
rates within the first month averaging 30%.[3] Identifying 
overt and covert predictors of morbidity and mortality after 
stroke is thus a major concern for clinicians, as an initial 
step that can guide the implementation of strategies to 
improve outcome.
An increasing body of evidence has linked inflammation 
with the pathogenesis of atherothrombotic stroke. 
Infections and inflammation may promote atherosclerosis 
and thrombosis by elevating serum levels of fibrinogen, 
leucocytes, clotting factors, and cytokines, and altering 
the metabolism and function of endothelial cells and 
monocytes/macrophages.[4‑8] C‑reactive protein (CRP) is 
an acute phase reactant and an indicator of underlying 
systemic inflammation that is a relatively novel plasma 
marker for atherothrombotic disease. The use of highly 
sensitive CRP assays has enhanced the usefulness of CRP 
as a reliable predictor of cardiovascular events. Large 
prospective studies in apparently healthy subjects have 
proposed that independent of other cardiovascular risk 
factors, elevated plasma CRP levels significantly predict 
the risk of future ischaemic stroke and transient ischaemic 
attack.[9,10] The prognostic significance of serum CRP in 
acute ischaemic stroke among white populations has been 
evaluated in several studies.[11‑13] While most studies have 
found that increased levels of CRP are associated with worse 
clinical outcome in patients with acute ischaemic stroke, 
in one study, CRP was not found to be a useful marker to 
predict the outcome of an acute cerebrovascular event in 
hospitalized patients.[11‑13]
The role of CRP as a prognostic marker of stroke outcome 
in Nigerians is not known, and it is desirable to determine 
its significance considering the potential therapeutic 
implications. The present study was designed to evaluate 
the relationship between serum CRP levels determined at 
admission for acute ischemic stroke, and short‑term stroke 
outcome in Nigerians.
Materials and Materials
The study was a prospective case‑control study enrolling 
consecutive patients presenting with first‑ever acute 
ischaemic stroke cases and hospitalized in the medical 
wards of the Lagos University Teaching Hospital (LUTH), 
Lagos State, Nigeria. Approval of the study protocol was 
obtained from the Health Research Ethics committee of the 
institution. The inclusion criteria were: Admission within 
7 days of onset of stroke symptoms, first‑ever ischaemic 
stroke. Stroke was defined as ‘rapidly developing symptoms 
or sign of focal and/or global cerebral dysfunction lasting more 
than 24 hrs or leading to death with no apparent cause other 
than of a vascular origin.[14] Brain computerized tomography 
(CT) scans were obtained in the majority of cases, and were 
reviewed by the study radiologists to document ischaemic 
strokes, exclude intracerebral haemorrhages and other 
conditions that may mimic stroke including intracranial 
space occupying lesions. In the few instances were brain 
CT was not available, ischaemic stroke was diagnosed 
using both the World Health Organization (WHO) clinical 
criteria, and the Siriraj stroke score criteria for ischaemic 
stroke.[15] The study excluded patients with haemorrhagic 
stroke, underlying known chronic inflammatory conditions 
(e.g., connective tissue disease, inflammatory bowel 
diseases), recent history of fever (within last seven days 
prior to onset of symptoms of stroke, patients with history 
(within preceding three months) of myocardial infarction, 
surgery, angiography, malignancies, statin therapy, steroid 
or non‑steroidal anti‑inflammatory drug use. Control 
subjects (ratio 1 to 2 cases) were healthy volunteers and 
were age‑(±2 years) and sex‑matched to cases. The same 
exclusion criteria were applied as for the cases. All cases 
were managed using a standardized protocol adapted from 
international guidelines for managing acute ischemic stroke, 
and incorporating our local standard of hospitalization of all 
strokes for 30 days. Thrombolytic therapy was not available.
Stroke severity on admission was assessed using the National 
Institute of Health Stroke Scale (NIHSS). The NIHSS is 
a 15‑item impairment scale which provides a quantitative 
measure of key components of standard neurological 
examination.[16] Admission NIHSS score was used to classify 
stroke severity as follows: Mild <8; moderate 8‑16; and 
severe ≥17.[17]
Serum CRP determination
Blood samples were obtained by venepuncture at admission 
and serum was then separated by centrifugation at 3000 
revolutions per minute for 10 minutes. The serum samples 
were refrigerated at the Central Research Laboratory 
of the institution at minus 30oC until batch analyzed. 
Serum CRP levels were determined using the particle‑
enhanced immunoturbidimetric test. This involved an 
antigen– antibody reaction between antibodies to human 
CRP bound to polystyrene particle and CRP in the sample and 
measured at a wavelength of 340 nm using the Hitachi ®‑905 
auto analyzer. The first run of tests was done using universal 
application which allowed for an extremely wide measuring 
range of 0.3 mg/L to 350 mg/L. The samples with CRP values 
less than 0.3 mg/L were re‑analyzed using a high sensitivity 
application (with the analyzer re‑calibrated) with a measuring 
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range of 0.05 mg/L to 20 mg/L. The cutoff value for defining 
elevated CRP was set as any value two standard deviations 
above the mean serum CRP obtained for controls
Outcome evaluation
All cases were followed up for the entire 30 day period 
in‑hospital. Outcome was determined using the Glasgow 
Outcome Scale. The functional status of patients who 
survived up to day 30 post‑stroke was assessed using the 
modified Rankin scale (MRS). MRS score of 0‑2 was 
graded favorable outcome (no symptoms/slight disability), 
while a score of 3‑5 was graded as unfavorable outcome 
(moderate/ severe disability).[18]
Statistical analysis
Data analysis was performed using Statistical Package for 
the Social Sciences (SPSS) ® version 13.0. Categorical 
data are summarized as frequencies and percentages 
while continuous data are described as mean values ± 
standard deviation (SD). Comparison of group differences 
in categorical variables was achieved using X2 test, while 
the Student’s t‑test and Mann Whitney U test were used 
to compare means of continuous normally distributed 
and non‑normally distributed variables respectively. The 
relationship between admission CRP and outcome scores 
(MRS and GOS) was determined using linear regression 
analysis. Statistical significance was set at P < 0.05.
Results
The study recruited a total of 138 acute ischaemic stroke 
cases but only 80 fulfilled the predetermined inclusion 
criteria and were included in the analysis. 58 were excluded 
from the study for the following reasons: 20 ischemic strokes 
presented after 7 days of onset; 18 had documented fever at 
presentation; and 7 were on non‑steroidal anti‑ inflammatory 
drugs/steroids at the time of the event. 13 of the cases who 
did not have brain CT scan and whose Siriraj stroke scores 
were between ‑1 and +1 were also excluded.
Baseline characteristics are shown in Table 1. The stroke 
cases comprised of 47 men (58.8%) and 33 women (41.3%), 
while the controls were 27 men (67.5%) and 13 women 
(32.5%). There was no significant difference in gender 
distribution of cases and controls (X2 = 0.53; P = 0.47). 
The ages of the stroke cases ranged from 13 to 91 years, 
(mean age ± SD of 59.10 ± 15.02 years). The age range 
of the controls was 14 to 73 years (mean age ± SD of 
56.13 ± 10.61) (T = 1.12; P = 0.27). Hypertension was 
the most common modifiable risk factor for stroke [Table 1].
Serum CRP levels and relationship to disease‑ related 
parameters
Based on the mean CRP in controls, elevated CRP was 
defined in this study as any value exceeding 4.5 mg/L. 
The mean admission serum CRP level (mg/L) for stroke 
cases was 17.7 ± 14.4, compared to controls 1.1 ± 1.7 
(P < 0.00001). Thus, the frequency of elevated CRP was 
76.3% (n = 61) in stroke cases and 5% (n = 2) in controls. 
This difference was statistically significant (X2 = 51.5, Fisher 
exact P < 0.00001).
The mean CRP in subgroups of stroke patients defined based 
on severity of stroke (NIHSS category) and stroke outcome 
measures (GOS and MRS) are shown in Table 2 and 
Figure 1. Overall case fatality rate was 25% (n = 20). Mean 
serum admission CRP was significantly higher in patients 
that died within the 30‑day follow up period compared to 
survivors. Patients who recovered completely or had mild 
disability (favorable outcome) had significantly lower mean 
admission CRP levels compared to those with unfavorable 
outcome (moderate/severe disability).
Fgure 1: Admission serum CRP levels across the spectrum of 
outcomes on the Glasgow Outcome Scale at 30 days post-stroke
Table 1: Baseline characteristics of ischaemic stroke 




Mean blood pressure±standard deviation (mmHg)
Systolic 156.5±30.4
Diastolic 91.4±17.1
Risk factor profile N (%)
Systemic hypertension 62 (77.5)
Diabetes mellitus 24 (30.0)
Cigarette smoking 9 (11.3)
Cardiac diseases* 2 (2.50)
Sickle cell anaemia 1 (1.3)
NIHSS score (mean±SD) 8.1±3.1




*Dilated cardiomyopathy=1, atrial fibrillation=1
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In multivariate regression analysis [Table 3], only high 
NIHSS score and admission CRP were predictors of case 
fatality. Other variables included in the model i.e., age at 
stroke onset, mean arterial pulse (MAP), pulse pressure 
(PP), duration prior to presentation were not found to be 
independent predictors of case fatality.
Discussion
This study found significantly higher CRP levels on admission 
in acute ischemic stroke patients compared to controls, and 
validates previous publications indicating that CRP levels 
tend to be elevated in the post‑stroke period,[11,12] typically 
representing an acute inflammatory phase reaction, and 
possibly reflecting the underlying role of inflammation in 
the pathogenesis of ischaemic stroke. Our study, conducted 
using a documented, from a prospective design incorporating 
population controls, documented a similarly high frequency 
of elevated CRP (76.3%) in acute ischemic stroke in 
Nigerians, comparable to data from other populations. 
Di Napoli et al.[12] reported a frequency of elevated CRP 
of 74.2% in their Caucasian patients with acute ischaemic 
stroke. Genetic differences are known to modify CRP 
concentrations post‑stroke, as illustrated by Ben‑Assayag 
et al. who showed that genetic variation in the promoter 
region of the CRP gene influences the triggered serum CRP 
concentration following acute stroke. During acute stroke, 
individuals with the CRP 717 AG/GG genotype have more 
significant elevation in CRP concentration compared to 
those with the 717 AA genotype.[19]
Secondly, we found a positive association between admission 
CRP and severity of stroke at presentation. This may 
reflect the relationship between the magnitude of the acute 
inflammatory response and the extent of ischaemia. More 
profound necrosis results in a greater degree of inflammation 
and higher levels of circulating acute phase proteins. Human 
studies have shown a direct correlation of interleukin (IL) 6 
levels with extent of tissue damage in stroke.[20] This is also 
consistent with the finding that case fatality rate was highest 
in those with elevated CRP levels in this study, while none of 
the patients with normal CRP died within the study period, 
marking elevated CRP as a predictor of adverse outcome 
post‑acute ischaemic stroke. Rallidis et al.[21] also reported 
significantly higher mean CRP of 25.2 mg/L in stroke cases 
who died in their study, compared to survivors (3.2 mg/L).
Table 2: Mean admission serum CRP and relationship with 30-day post-stroke outcome
Characteristic Mean CRP±SD (mg/L) t statistic P value
Admission CRP values
Stroke cases (n=80) 17.7±14.4 7.22 <0.00001
Controls (n=40) 1.1±1.7
Admission stroke severity
Mild stroke (n=31) 7.9±8.5 5.72 <0.00001
Moderate/severe stroke (n=49) 23.9±3.8
30-day case fatality
Died (n=20) 34.6±8.9 8.33 <0.00001
Survived (n=60) 12.0±11.0
Length of survival
Died ≤7 days (n=6) 43.6±0.8 16.78 <0.00001
Died 8-14 days (n=5) 38.3±3.3
Died15-21 days (n=5) 28.5±6.8
Died 22-30 days (n=4) 24.5±6.7
30-day functional outcome among survivors (n=60)
Favorable outcome (MRS 0-2) (n=38) 6.5±6.2 6.7 <0.00001
Unfavorable outcome (MRS 3-5) (n=22) 21.5±11.1
MRS = Modified Rankin scale. Boxplot showing increasing admission CRP levels (mg/L) (median and interquartile ranges) with worsening GOS score (from 
best outcome 1 to worst outcome 5). Numbers within background indicate outliers in the subcategory of patients with GOS 1
Table 3: Determinants of 30-day case fatality in multiple regression analysis
Parameter Odds ratio 95% confidence interval P value
Admission diastolic blood pressure 2.31 0.31-17.46 0.42
Admission mean arterial pressure 1.28 0.65-2.54 0.48
Admission pulse pressure 0.45 0.06-3.27 0.43
Age (years) 0.98 0.90-1.08 0.74
CRP value (mg/L) 1.24 1.06-1.44 0.008
Admission NIHSS score 3.43 1.49-7.94 0.004
Duration prior to presentation (hours) 1.01 0.98-1.05 0.49
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Furthermore, we found a positive association between 
admission CRP and functional outcome. This is similar to 
the finding of Di Napoli et al.[12] who demonstrated that 
increased levels of admission CRP are associated with worse 
outcome in patients with acute ischaemic stroke. Although 
the precise pathophysiological basis of this association is 
unclear, there are certain possible explanations. Firstly, 
CRP concentration may reflect the degree of inflammation 
directly consequent upon cerebral infarction. Elevated CRP 
levels may reflect a greater extent of brain necrosis[22] and a 
greater amount and activity of pro‑inflammatory cytokines 
which may potentiate ischaemic brain injury through several 
mechanisms such as up regulation of adhesion molecules, 
recruitment and activation of leucocytes and potentiation of 
local pro‑coagulant state.[23] Secondly, CRP concentration 
on admission could also be predictive of outcome as baseline 
CRP may be indicative of underlying unstable atherosclerotic 
disease, the presence of which is a risk factor for other 
co‑morbid states such as ischaemic heart disease which 
can worsen stroke outcome. Thirdly, CRP may be raised 
as a consequence of covert complications of stroke such 
as infections and aspiration. Even though strict inclusion 
criteria were applied, it is difficult to exclude, for instance, 
early asymptomatic stages of infection which could both 
compound stroke‑specific CRP elevation and disease course.
Limitations
We acknowledge the modest size of the sample studied and 
indicate that our findings, though preliminary in nature, 
provide a thrust for larger, more elaborate studies. Also, a 
small minority of cases did not have a brain CT scan and 
clinical validated criteria were used for characterization as 
ischemic stroke. It was beyond the scope of this study to 
explore other covert contributions to elevated CRP levels, 
and we realize that these may exist. However, we have 
illustrated that elevated CRP is a frequent accompaniment 
of ischaemic stroke in our environment, correlates with 
stroke severity, and independently predicts adverse outcome 
including fatality and functional impairment. Our study 
buttresses the existing view that inflammation is a significant 
factor in ischemic stroke, and supports the need for scientific 
research focusing on establishing the relationship between 
inflammation and ischemic stroke.
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